2021-07-28-世界卫生组织-Priorities_of_the_Global_Leaders_Group_on_AMR_for_2021-2022_6页_547kb

Summary of the Global Leaders Group on AMR 2021-2022 Action Plan

Core Mission

The Global Leaders Group (GLG) on Antimicrobial Resistance (AMR) aims to collaborate globally with governments, agencies, civil society, and the private sector through a One Health approach to advise and advocate for political action to mitigate drug-resistant infections by promoting responsible and sustainable access and use of antimicrobials.

Priority 1: Sustained Political Action on AMR

Outcome

AMR is recognized and acted upon as a major threat to health and development in global and national frameworks, with mitigation efforts guided by a One Health approach.

Key Performance Indicators

• AMR is highly prioritized in all relevant international agendas and frameworks.
• Global pandemic treaty includes AMR.
• Percentage of global COVID-19 response and recovery plans that include AMR.
• Number of GLG members attending key events advocating for AMR priorities.

Key Activities

• Mapping and prioritization exercise to identify key opportunities and gaps.
• GLG-commissioned reports and advocacy statements with targeted calls to action.
• Advocacy for inclusion of AMR in global health security plans and any global pandemic treaty.
• Advocacy for a High Level Meeting on AMR at UNGA in 2024 or 2026.
• Promotion of key messages in national, regional, and global fora.
• Reporting to the Tripartite, UNEP, and UN Secretary General on global progress and gaps.

Deliverables 2021

• Internal mapping document by the Secretariat to support prioritization and collective actions.
• GLG communications and engagement strategy.

Priority 2: Transforming Ecosystems for AMR Mitigation

Outcome

Infection prevention and control, including WASH, biosecurity, vaccination, and waste management, are prioritized as interventions to mitigate AMR across all sectors.

Key Performance Indicators

• Increased percentage of Tripartite and UNEP products that include IPC and WASH.
• Increased number of countries prioritizing IPC as key interventions.
• Number of sector-specific pledges to reduce antimicrobial release into the environment.
• Number of countries eliminating over-the-counter and internet sales of antimicrobials.
• Number of countries eliminating use of Highest Priority-Critically Important Antimicrobials for growth promotion.

Key Activities

• Advocacy for IPC and antimicrobial stewardship in all sectors.
• Promotion of access to affordable diagnostics, vaccines, and non-antimicrobial alternatives.
• Advocacy for national governance and professional oversight of antimicrobial use.
• Development of evidence-based guidelines for treatment, control, and prevention.

Deliverables 2021

• Targeted GLG working group discussion on antimicrobial use in food systems.
• Mapping of Tripartite and UNEP work on AMR, IPC, and WASH.
• GLG statement on antimicrobial use in food systems.

Priority 3: Improved Surveillance and Monitoring

Outcome

Global and national actions on AMR are guided by science- and risk-based data on antimicrobial use and resistance.

Key Performance Indicators

• Number of countries performing integrated AMR surveillance across sectors.
• Number of countries with global and national targets for responsible antimicrobial use.
• Number of stakeholders developing voluntary targets for AMR surveillance.

Key Activities

• Promoting coherence and best practices in AMR surveillance.
• Advocacy for the development and implementation of Codex Guidelines on Integrated Monitoring.
• Promoting global genomic surveillance of AMR with priority pathogens.
• Liaising with Tripartite, UNEP, and other organizations to advance a coherent One Health surveillance approach.

Deliverables 2021

• Liaising with the Independent Panel on Evidence for Action against AMR.
• Encouraging development and improvement of AMR surveillance mechanisms.
• Promoting laboratory strengthening initiatives.
• Stock take of global AMR surveillance mechanisms.
• GLG information note on AMR surveillance.

Priority 4: Enhanced Funding for AMR Response

Outcome

Increased, sustainable public and private investment in AMR across all sectors, with a focus on Low- and Middle-Income Countries (LMICs).

Key Performance Indicators

• Increased number of countries with funded and implemented national action plans.
• Increased number of financing mechanisms supporting national action plans in LMICs.
• Number of new global and national funding partnerships.
• Amount of new AMR funding by donors to LMICs.
• Increased core funding for AMR by GLG members to Tripartite and UNEP.
• Adoption of a One Health lens by key investors and banks.

Key Activities

• Advocacy for increased investment in AMR through national action plans.
• Support for the AMR Multi-Partner Trust Fund and other funding mechanisms.
• Exploration of mechanisms to incentivize countries to act on AMR.
• Advocacy for a One Health financing approach.
• Support for the development of an AMR investment case.
• Promotion of a business environment that encourages healthy production choices.
• Promotion of the Investor Action on AMR² initiative.

Deliverables 2021

• GLG statement on the need for enhanced funding for AMR, especially in LMICs.
• GLG information note on financing for AMR response.
• Mapping and analysis of funding shortfalls in LMICs.

Priority 5: Innovation for AMR Response

Outcome

Increased, effective, and affordable innovations across all sectors to secure a sustainable pipeline of new antimicrobials, vaccines, diagnostics, and alternatives, with equitable access.

Key Performance Indicators

• Inclusion of AMR investment and innovation pledges in political statements.
• Number of countries implementing new approaches to attract sustainable investment.
• Number of R&D stakeholders targeting new medicines and alternatives.

Key Activities

• Advocacy for specific investment commitments by governments and the private sector.
• Promotion of mechanisms recognizing the value of novel antimicrobials and enabling patient access.
• Advocacy to address financial and regulatory barriers to innovation.
• Support for whole-of-government dialogue on AMR.

Deliverables 2021

• GLG statement to solicit pledges from G7, G20, OECD, and regional blocs.
• GLG statements promoting specific R&D areas such as phage therapy and gene editing.

Priority 6: Understanding Environmental Pathways to AMR

Outcome

Better understanding of environmental pathways to the development and transmission of AMR.

Key Performance Indicators

• Environmental aspects of AMR included in Tripartite and UNEP strategies.
• Number of new commitments by stakeholders to reduce antimicrobial discharge in manufacturing.

Key Activities

• Review and comment on UNEP reports on environmental AMR.
• Development of position papers on antimicrobial waste, discharge in food systems, and healthcare facilities.
• Advocacy around G7 and G20, with focus on prevention and SDG6.
• Promotion of existing guidance on WASH and wastewater management.
• Advocacy for integrated surveillance of antimicrobial discharge and AMR determinants.
• Encouragement of private sector data use for environmental AMR understanding.
• Advocacy for prevention of AMR in the context of sustainable biodiversity at COP26, G7, and G20.

Deliverables 2021

• Targeted GLG working group discussion on environment and AMR.
• GLG statement on environment and AMR, emphasizing sustainable biodiversity.
• Position papers on antimicrobial manufacturing waste, food system discharge, and hospital discharge.
• GLG information note on AMR and climate change.